South Korea vs Peru: Statin use vs. average non-HDL cholesterol levels
South Korea
3.4
in 2018
Peru
3.4
in 2018
South Korea rank
75th
Peru rank
75th
Statin use vs. average non-HDL cholesterol levels over time
- South Korea
- Peru
How they compare
South Korea currently reports 3.4 against 3.4 in Peru, a difference of 0.
The two have swapped places 4 times across 39 shared years of data; in 1980 it was Peru ahead.
South Korea ranks 75th and Peru ranks 75th of 191 countries.
Across the 4 decades both report, South Korea averaged higher in 2 and Peru in 1.
Head to head by decade
| Decade | South Korea | Peru | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.56 | 3.59 | 0.03 | Peru |
| 1990s | 3.6 | 3.6 | 0 | — |
| 2000s | 3.56 | 3.51 | 0.05 | South Korea |
| 2010s | 3.49 | 3.44 | 0.0444 | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, South Korea or Peru?
- South Korea, at 3.4 against 3.4 in Peru as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between South Korea and Peru?
- 0, with South Korea ahead.
- How many years of comparable data are there for South Korea and Peru?
- 39 years are reported by both, from 1980 to 2018.
- How do South Korea and Peru rank globally for statin use vs. average non-hdl cholesterol levels?
- South Korea ranks 75th and Peru ranks 75th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.